Skip to main content
SpringerLink
Log in

Ganoderic Acid for Anticancer Applications: Scope of Nanomedicine in Its Effective Delivery

  • Chapter
  • First Online:
Nanomedicine for Bioactives

  • 430 Accesses

Abstract

Ganoderma lucidum is a mushroom; traditionally, it has been used from long history of medicinal use in China, Japan, and Korea. The main active constituents of Ganoderma lucidum is ganoderic acid (GA). GA is a triterpenoid, which is derived from lanosterol. Since several decades, the fruiting bodies of Ganoderma fungi have been widely used for human healthcare applications. GA has been reported for treatment of several dreadful disorders including hepatoprotective, hepatocellular carcinoma, immunomodulating action, anti-inflammatory, antidiabetic, antioxidants, and free radical scavenging action. The most active constituent related to the biological action is GA-DM, which is obtained from G. lucidum. This chapter discussed GA-DM as potential therapeutic candidate for treatment of number of diseases as an alternative or supplemental therapeutic agent in treating various cancer. Therefore, the mechanistic action of GA-DM is also discussed, which is capable of inducing cell death in cancer cells by action such as immunostimulant, apoptotic, and autophagic pathways in various cancer. Overall, this chapter extensively covers the history of G. lucidum and its traditional use and therapeutic application against cancer with molecular mechanism based on in vitro and in vivo experiments.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Rahman M, Ahmad MZ, Kazmi I, Akhter S, Afzal M, Gupta G et al (2012) Advancement in multifunctional nanoparticles for the effective treatment of cancer. Expert Opin Drug Deliv 9(4):367–381

    Article  CAS  Google Scholar 

  2. Lindequist U, Niedermeyer TH, Julich WD (2005) The pharmacological potential of mushrooms. Evid Based Complement Alternat Med 2:285–299

    Article  Google Scholar 

  3. Wasser SP (2011) Current findings, future trends, and unsolved problems in studies of medicinal mushrooms. Appl Microbiol Biotechnol 89:132313–132332

    Article  Google Scholar 

  4. Wu GS, Lu JJ, Guo JJ, Li YB, Tan W et al (2012) Ganoderic acid DM, a natural triterpenoid, induces DNA damage, G1 cell cycle arrest and apoptosis in human breast cancer cells. Fitoterapia 83:408–414

    Article  CAS  Google Scholar 

  5. Radwan FF, Perez JM, Haque A (2011) Apoptotic and immune restoration effects of ganoderic acids define a new prospective for complementary treatment of cancer. J Clin Cell Immunol S3:4

    PubMed  Google Scholar 

  6. Bishop KS, Kao CH, Xu Y, Glucina MP, Paterson RR et al (2015) From 2000 years of Ganoderma lucidum to recent developments in nutraceuticals. Phytochemistry 114:56–65

    Article  CAS  Google Scholar 

  7. Wachtel-Galor S, Yuen J, Buswell JA, Benzie IFF (2011) Ganoderma lucidum (Lingzhi or Reishi): a medicinal mushroom (Chapter 9) In: Benzie IFF, Wachtel-Galor S (eds) Herbal medicine: biomolecular and clinical aspects, 2nd ed. CRC Press/Taylor & Francis, Boca Raton, FL

    Google Scholar 

  8. Radwan FF, Hossain A, God JM, Leaphart N, Elvington M et al (2015) Reduction of myeloid-derived suppressor cells and lymphoma growth by a natural triterpenoid. J Cell Biochem 116:102–114

    Article  CAS  Google Scholar 

  9. Huang SZ, Ma QY, Kong FD, Guo ZK, Cai CH et al (2017) Lanostane-type triterpenoids from the fruiting body of Ganoderma calidophilum. Phytochemistry 143:104–110

    Article  CAS  Google Scholar 

  10. Wei JC, Wang AH, Wei YL, Huo XK, Tian X et al (2017) Chemical characteristics of the fungus Ganoderma lucidum and their inhibitory effects on acetylcholinesterase. J Asian Nat Prod Res 20(10):1–10

    Google Scholar 

  11. Liu J, Shimizu K, Tanaka A, Shinobu W, Ohnuki K et al (2012) Target proteins of ganoderic acid DM provides clues to various pharmacological mechanisms. Sci Rep 2:905

    Article  Google Scholar 

  12. Akihisa T, Nakamura Y, Tagata M, Tokuda H, Yasukawa K et al (2007) Anti-inflammatory and anti-tumor-promoting effects of triterpene acids and sterols from the fungus Ganoderma lucidum. Chem Biodivers 4:224–231

    Article  CAS  Google Scholar 

  13. Shi L, Ren A, Mu D, Zhao M (2010) Current progress in the study on biosynthesis and regulation of ganoderic acids. Appl Microbiol Biotechnol 88:1243–1251

    Article  CAS  Google Scholar 

  14. Xia Q, Zhang H, Sun X, Zhao H, Wu L et al (2014) A comprehensive review of the structure elucidation and biological activity of triterpenoids from Ganoderma spp. Molecules 19:17478–17535

    Article  Google Scholar 

  15. Hossain A, Radwan FF, Doonan BP, God JM, Zhang L et al (2012) A possible cross-talk between autophagy and apoptosis in generating an immune response in melanoma. Apoptosis 17:1066–1078

    Article  CAS  Google Scholar 

  16. Shafei A, El-Bakly W, Sobhy A, Wagdy O, Reda A et al (2017) A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer. Biomed Pharmacother 95:1209–1218

    Article  CAS  Google Scholar 

  17. Johnson BM, Doonan BP, Radwan FF, Haque A, Ganoderic Acid DM (2010) An alternative agent for the treatment of advanced prostate cancer. Open Prost Cancer J 3:78–85

    Article  CAS  Google Scholar 

  18. Hoelzer D, Gökbuget N (2012) Chemoimmunotherapy in acute lymphoblastic leukemia. Blood Rev 26:25–32

    Article  CAS  Google Scholar 

  19. Opat S, Hawkes EA (2017) Chemoimmunotherapy may not be dead yet in chronic lymphocytic leukemia, but fludarabine plus cyclophosphamide plus rituximab is potentially facing life support. J Clin Oncol 2017:4093–4094

    Article  Google Scholar 

  20. Reddy NM, Thieblemont C (2017) Maintenance therapy following induction chemoimmunotherapy in patients with diffuse large B-cell lymphoma: current perspective. Ann Oncol 28:2680–2690

    Article  CAS  Google Scholar 

  21. Rahman M, Al-Ghamdi SA, Sharma K, Beg S, Alharbi KS, Abbasi FA et al Ganoderic acid loaded nano-lipidic carriers improvise treatment of hepatocellular carcinoma. Drug Deliv. https://doi.org/10.1080/10717544.2019.1606865

  22. Zhang W, Yu W, Ding X, Yin C, Yan J, Yang E et al (2019) Self-assembled thermal gold nanorod-loaded thermosensitive liposome-encapsulated ganoderic acid for antibacterial and cancer photochemotherapy. Artif Cells Nanomed Biotechnol 47(1):406–419

    Article  CAS  Google Scholar 

  23. Sumanasuriya S, De Bono J (2018) Treatment of advanced prostate cancer-a review of current therapies and future promise. Cold Spring Harb Perspect Med. https://doi.org/10.1101/cshperspect.a030635

  24. Bhutia SK, Dash R, Das SK, Azab B, Su ZZ et al (2010) Mechanism of autophagy to apoptosis switch triggered in prostate cancer cells by antitumor cytokine melanoma differentiation-associated gene 7/interleukin-24. Cancer Res 70:3667–3676

    Article  CAS  Google Scholar 

  25. Aoun F, Bourgi A, Ayoub E, El Rassy E, van Velthoven R et al (2017) Androgen deprivation therapy in the treatment of locally advanced, nonmetastatic prostate cancer: practical experience and a review of the clinical trial evidence. Ther Adv Urol 9:73–80

    Article  Google Scholar 

  26. Rucci N, Angelucci A (2014) Prostate cancer and bone: the elective affinities. Biomed Res Int 2014:167035

    Article  Google Scholar 

  27. Lee N, Barthel SR, Schatton T (2014) Melanoma stem cells and metastasis: mimicking hematopoietic cell trafficking? Lab Investig 94:13–30

    Article  CAS  Google Scholar 

  28. Haque MA, Li P, Jackson SK, Zarour HM, Hawes JW et al (2002) Absence of gamma-interferon-inducible lysosomal thiol reductase in melanomas disrupts T cell recognition of select immunodominant epitopes. J Exp Med 195:1267–1277

    Article  CAS  Google Scholar 

  29. Hathaway-Schrader JD, Doonan BP, Hossain A, Radwan FFY, Zhang L et al (2018) Autophagy-dependent crosstalk between GILT and PAX-3 influences radiation sensitivity of human melanoma cells. J Cell Biochem. https://doi.org/10.1002/jcb.26383

  30. Sotgia F, Fiorillo M, Lisanti MP (2017) Mitochondrial markers predict recurrence, metastasis and tamoxifen-resistance in breast cancer patients: early detection of treatment failure with companion diagnostics. Oncotarget 8:68730–68745

    Article  Google Scholar 

  31. Das A, Miller R, Lee P, Holden CA, Lindhorst SM et al (2015) A novel component from citrus, ginger, and mushroom family exhibits antitumor activity on human meningioma cells through suppressing the Wnt/beta-catenin signaling pathway. Tumour Biol 36:7027–7034

    Article  CAS  Google Scholar 

  32. Ragel BT, Jensen RL, Gillespie DL, Prescott SM, Couldwell WT et al (2005) Ubiquitous expression of cyclooxygenase-2 in meningiomas and decrease in cell growth following in vitro treatment with the inhibitor celecoxib: potential therapeutic application. J Neurosurg 103:508–517

    Article  CAS  Google Scholar 

  33. Piscevic I, Villa A, Milićević M, Ilić R, Nikitović M et al (2015) The influence of adjuvant radiotherapy in atypical and anaplastic meningiomas: a series of 88 patients in a single institution. World Neurosurg 83:987–995

    Article  Google Scholar 

  34. Preusser M, Berghoff AS, Hottinger AF (2013) High-grade meningiomas: new avenues for drug treatment? Curr Opin Neurol 26:708–715

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Sciences, Shalom Institute of Health & Allied Sciences, SHUATS, Allahabad, Uttar Pradesh, India

    Mahfoozur Rahman

Authors
  1. Mahfoozur Rahman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pharmaceutical Sciences, Shalom Institute of Health & Allied Sciences, SHUATS, Allahabad, Uttar Pradesh, India

    Mahfoozur Rahman

  2. Nanomedicine Research Lab, School of Pharmaceutical Education & Research, Jamia Hamdard, New Delhi, India

    Sarwar Beg

  3. Department of Pharmaceutical Sciences, Shalom Institute of Health & Allied Sciences, SHUATS, Allahabad, Uttar Pradesh, India

    Vikas Kumar

  4. Nanomedicine Research Lab, School of Pharmaceutical Education & Research, Jamia Hamdard, New Delhi, India

    Farhan Jalees Ahmad

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Rahman, M. (2020). Ganoderic Acid for Anticancer Applications: Scope of Nanomedicine in Its Effective Delivery. In: Rahman, M., Beg, S., Kumar, V., Ahmad, F. (eds) Nanomedicine for Bioactives . Springer, Singapore. https://doi.org/10.1007/978-981-15-1664-1_1

Download citation

Publish with us

Policies and ethics

Search

Navigation